The executive director of the Association of Movement Disorder Advanced Practice Providers talked about a recent survey highlighting why patients with movement disorders may withhold critical health information from their providers.
The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]
Approximately 83% of patients reported that they did not disclose to their provider that they experienced symptoms or had concerns about living with a movement disorder.
As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Kelly Papesh, DNP, APRN, FNP-BC, executive director of the Association of Movement Disorder Advanced Practice Providers.
In collaboration with Robert A. Hauser, MD, MBA, the survey aims to understand the impact of tremors in patients with Parkinson disease.
The clinical director of Parkinson & Movement Disorder Alliance shared her thoughts on potential therapies to increase management care options for patients with Parkinson disease. [WATCH TIME: 5 minutes]
The chief executive officer at Parkinson & Movement Disorder Alliance and the president at PD Avengers discussed the importance of awareness in movement disorders and the challenges that patients still face in getting access to treatments for improved quality of life. [WATCH TIME: 12 minutes
The professor of neurology and residency program director at MedStar Georgetown University Hospital spoke to the evolution of the utility of botulinumtoxins in the treatment of patients with Parkinson and other movement disorders. [WATCH TIME: 4 minutes]
Clinicians must be armed with fact-based information on all treatment options especially newer medications and technologies—good clinical care must be both patient-centric and knowledge-driven.
Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida, provided insight on the therapeutic potential of IPX203, and why it adds flexibility to the treatment of Parkinson disease.
The nurse practitioner at the University of Southern California Keck Medical School provided insight on steps before deep brain stimulation and how they can impact outcomes for patients with Parkinson disease. [WATCH TIME: 4 minutes]
Pooled results of a post hoc analysis from phase 3 studies of amantadine (Gocovri; Supernus) suggest that the therapy offers increased good ON time, and in intervals that are more predictable for patients, compared with placebo.
The assistant professor of neurology and director of the Movement Disorders Outreach Program at Mount Sinai Medical Center shed some light on the use of DBS in the clinic and how it has evolved as a therapeutic option for patients with Parkinson disease. [WATCH TIME: 2 minutes]
The executive director of the newly launched Association of Movement Disorder Advanced Practice Providers provided an overview of the organization and what it can offer to APPs. [WATCH TIME: 4 minutes]
Data from the phase 3 KINECT-HD study of valbenazine (Neurocrine Biosciences) provided a keen understanding of the threshold for clinically meaningful improvement in TMC scores. The VMAT2 inhibitor showed promising gains for patients.
The panel of movement disorder specialists and dermatologists offered a framework of suggestions for the supervision of the most common infusion-site reaction associated with these therapies.
Data from an interventional survey suggest that patients with a better understanding of social participation’s benefits may be more confident to participate in social situations and events.
A survey of more than 700 Parkinson disease caregivers highlighted the impact their role has on them emotionally, physically, and mentally, and pointed to several areas of need for support from the clinical community.
The assistant professor of neurology and director of the Movement Disorders Outreach Program at Mount Sinai Medical Center spoke about the challenges with access to care in movement disorders. [WATCH TIME: 2 minutes]
The professor of neurology and residency program director at MedStar Georgetown University Hospital discussed the value of educating clinicians on the utility of botulinumtoxins in PD care. [WATCH TIME: 3 minutes]
The director of the Movement Disorders Division at Loma Linda University discussed the importance of understanding good ON time in Parkinson disease care, and how it can influence quality of life. [WATCH TIME: 5 minutes]
The course director of ATMRD 2023 provided perspective on the notable strides made in the movement disorder field, including the significant progress made in drug delivery. [WATCH TIME: 5 minutes]
The course directors of the 2023 ATRMD Congress provided an overview of the upcoming meeting, and the educational benefits clinicians can gain from attending. [WATCH TIME: 6 minutes]
The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided perspective on the difficulties with testing agents for Parkinson disease psychosis, and the future outlook of treating the symptom. [WATCH TIME: 4 minutes]
The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute discussed the future of treating Parkinson disease psychosis, and potential ways to lower risk of poor long-term outcomes. [WATCH TIME: 3 minutes]
The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided detail on an educational course that examined medication management for Parkinson disease psychosis.
Gather in Washington, DC with renowned experts on June 8 – June 11, 2023.
